1-3 of 3
Karel Helman
Close
Sort by
Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 5996–5997.
https://doi.org/10.1182/blood-2022-168617
Published: 2022
Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Ondrej Havranek, Karel Helman, Magdalena Klanova, Miroslav Strnad, Marek Trneny, Pavel Klener, Jr.
Journal: Blood
Blood (2021) 138 (Supplement 1): 1203.
https://doi.org/10.1182/blood-2021-150517
Published: 2021
Journal Articles

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Magdalena Klanova, MD, Ladislav Andera, M.Sc. PhD, Jan Soukup, MDPhD, Brazina Jan, M.Sc., Jan Svadlenka, M.Sc., Simona Benesova, M.Sc., Dana Prukova, M.Sc. PhD, Dana Vejmelkova, M.Sc., Radek Jaksa, MD, Karel Helman, PhD, Petra Vockova, MD, Lucie Lateckova, MD, Jan Molinsky, MD PhD, Bokang Maswabi, MD, Mahmudul Alam, PhD, Roman Kodet, Prof. MD, Marek Trneny, Pavel Klener, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 3645.
https://doi.org/10.1182/blood.V124.21.3645.3645
Published: 2014